“Health, risks and disease in therapeutic functionalities of Glucagon-like peptide-1 receptoragonists (GLP-1RAs) concerning human susceptibility” (2025) Greenfort International Journal of Applied Medical Science, 3(5), pp. 240–254. doi:10.62046/gijams.2025.v03i05.002.